SEC Comment Letter 0000000000-26-003341 to Cellyan Biotechnology Co., Ltd (HKPD)

Cellyan Biotechnology Co., Ltd
Date: April 2, 2026 · CIK: 0002007702 · Accession: 0000000000-26-003341

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-294685

Date

April 2, 2026

Author

Division of

Form

UPLOAD

Company

Cellyan Biotechnology Co., Ltd

Letter

Re: Cellyan Biotechnology Co., Ltd Registration Statement on Form F-1 Filed March 27, 2026 File No. 333-294685 Dear Chinyu Liang:

April 2, 2026

Chinyu Liang Chief Executive Officer Cellyan Biotechnology Co., Ltd Room B1, 5/F., Well Town Industrial Building 13 Ko Fai Road, Yau Tong, Kowloon Hong Kong

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Kate Beukenkamp at 202-551-3861 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Trade &
Services
cc: Zhaocong "Richard" Xu

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           April 2, 2026

Chinyu Liang
Chief Executive Officer
Cellyan Biotechnology Co., Ltd
Room B1, 5/F., Well Town Industrial Building
13 Ko Fai Road, Yau Tong, Kowloon
Hong Kong

       Re: Cellyan Biotechnology Co., Ltd
           Registration Statement on Form F-1
           Filed March 27, 2026
           File No. 333-294685
Dear Chinyu Liang:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Kate Beukenkamp at 202-551-3861 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Trade &
Services
cc:    Zhaocong "Richard" Xu
</TEXT>
</DOCUMENT>

SecProbe.io